8:00 am Check-In & Light Breakfast

8:55 am Chair’s Opening Remarks

Refining Inflammasome-Driven Immune Modulation to Enable Meaningful Clinical Outcomes

9:00 am Spotlighting Phase II Clinical Data: Advancing GPCR19 Agonists for Patients with Atopic Dermatitis

• Shawn Seong Chief Executive Officer, Shaperon

9:30 am Immune Surveillance Upstream of NLRP3 Pathway: Clinical Insights on Diabetes & Retinal Disease

• Brian Levy Chief Executive Officer, InflammX Therapeutics

Unravelling Pathway Biology to Spotlight Untouched Activation Routes & Other Disease Links

10:00 am First-in-Class Caspase-4/5 Inhibition: Unlocking New Frontiers in Inflammasome Therapeutics

• Elad Elkayam Principal Investigator, Ventus Therapeutics

10:30 am Morning Refreshments & Networking

11:15 am Tissue-Specific Regulation of Neutrophils: Citrullination, Polarization & NLRP3 Targeting

• Denisa Wagner Professor, Pediatrics, Harvard Medical School

11:45 am Roundtable Discussion: Inflammasomes at the Frontier: Charting the Next Move of Therapeutic Innovation

• Hal Hoffman Professor, Pediatrics & Medicine, University of California, San Diego

12:30 pm Exploring the Gut-Brain Axis: Inflammasome-Mediated Inflammation & Pharmacological Inhibition Strategies

• Roberto De Luca Instructor of Neurology, Beth Israel Deaconess Medical Center (Harvard Medical School)
• Roberto Negro Senior Scientist, S. de Bellis